Treats agitation associated with schizophrenia or bipolar I disorder. Sold as Adasuve. Every FDA application for this active ingredient.
As of Nov 14, 2026, FDA lists 1 application for Loxapine (sold as Adasuve), first approved Dec 21, 2012, with 0 new uses approved and 0 published complete response letters.
| Product | Part | Spending, 2025 | Change | Beneficiaries |
|---|---|---|---|---|
| Loxapine | Part D | $3.6M | -1% | 7,588 |
| Program | Updated |
|---|---|
| Adasuve REMSRestricted: prescribers, pharmacies or patients must be certified or enrolled | May 11, 2026 |
| Approved | Application | Sponsor | Supplements | Marketing |
|---|---|---|---|---|
| Dec 21, 2012 | AdasuveNDA 22549 · New dosage form | Nova Pneuma | 5 | Marketed |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA
